Encompass Health Corporation

As of June 30, 2026, Encompass Health Corporation carries a market capitalization of 188.61B, placing it among publicly traded companies globally. Its enterprise value stands at 251.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Encompass Health Corporation's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Encompass Health Corporation has 98.80M shares outstanding.

As of June 30, 2026, Encompass Health Corporation trades at a trailing price-to-earnings ratio of 17.54. The price-to-sales ratio is 1.75, and the price-to-book ratio stands at 4.16.

As of June 30, 2026, Encompass Health Corporation trades at an EV/EBITDA multiple of 9.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.92 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Encompass Health Corporation trades at an EV/FCF ratio of 28.04, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 251.47B versus a market cap of 188.61B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Encompass Health Corporation maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 82.12, indicating elevated leverage, while an interest coverage ratio of 11.63 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Encompass Health Corporation posted a return on equity (ROE) of 25.46, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.67 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.72, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.42, useful for judging operating efficiency across full business cycles. The company generates approximately 2.60M in revenue per employee across its workforce of 41,725.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Encompass Health Corporation recorded 3.67B in income tax expense. That works out to an effective tax rate of 20.46, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 17.96B, leaving 10.85B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 9, 2026, Encompass Health Corporation's stock has gained approximately 10.49% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Encompass Health Corporation generated 108.43B in revenue and converted that into 10.85B in net income, yielding earnings per share of 141.12. EBITDA reached 25.51B, while operating income came in at 19.52B.

As of June 30, 2026, Encompass Health Corporation holds 1.88B in cash and equivalents against 49.66B in total debt, resulting in a net debt position of 44.14B. Total book value stands at 45.39B, with working capital of 2.93B providing operational flexibility.

Encompass Health Corporation produced 21.18B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -13.96B in capital expenditures, free cash flow totaled 7.22B - equivalent to 72.46 per share.

Over the twelve months ended June 30, 2026, Encompass Health Corporation posted a gross margin of 95.82, reflecting its pricing power and cost economics. The operating margin of 18.00 and net profit margin of 10.01 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Encompass Health Corporation paid dividends of 13.18 per share. The dividend payout ratio of 7.30 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.74, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.61, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Encompass Health Corporation shareholders.

Encompass Health Corporation's most recent stock split took place on October 26, 2006 with a 5:1 split ratio.

As of June 30, 2026, Encompass Health Corporation has an Altman Z-Score of 3.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.